View in EDS HTML Full Text PDF Full Text

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.

Saved in:
Bibliographic Details
Title: Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Authors: Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Roschewski MJ; National Cancer Institute, Bethesda, MD, USA., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA., Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA., Melear JM; Texas Oncology, Austin, TX, USA., Patel P; AstraZeneca, South San Francisco, CA, USA., Calvo R; AstraZeneca, Gaithersburg, MD, USA., Yang H; AstraZeneca, South San Francisco, CA, USA., Spurgeon SE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1728-1732. Date of Electronic Publication: 2022 Feb 24.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35200084
AccessLevel: 2
PubType: Report
PubTypeId: report
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Barr+PM%22">Barr PM</searchLink>; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.<br /><searchLink fieldCode="AU" term="%22Smith+SD%22">Smith SD</searchLink>; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Roschewski+MJ%22">Roschewski MJ</searchLink>; National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22O'Brien+SM%22">O'Brien SM</searchLink>; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sharman+JP%22">Sharman JP</searchLink>; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA.<br /><searchLink fieldCode="AU" term="%22Melear+JM%22">Melear JM</searchLink>; Texas Oncology, Austin, TX, USA.<br /><searchLink fieldCode="AU" term="%22Patel+P%22">Patel P</searchLink>; AstraZeneca, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Calvo+R%22">Calvo R</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Yang+H%22">Yang H</searchLink>; AstraZeneca, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Spurgeon+SE%22">Spurgeon SE</searchLink>; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1728-1732. <i>Date of Electronic Publication: </i>2022 Feb 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35200084
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2022.2043301
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1728
    Titles:
      – TitleFull: Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Barr PM
      – PersonEntity:
          Name:
            NameFull: Smith SD
      – PersonEntity:
          Name:
            NameFull: Roschewski MJ
      – PersonEntity:
          Name:
            NameFull: O'Brien SM
      – PersonEntity:
          Name:
            NameFull: Sharman JP
      – PersonEntity:
          Name:
            NameFull: Melear JM
      – PersonEntity:
          Name:
            NameFull: Patel P
      – PersonEntity:
          Name:
            NameFull: Calvo R
      – PersonEntity:
          Name:
            NameFull: Yang H
      – PersonEntity:
          Name:
            NameFull: Spurgeon SE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2022 Jul
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 63
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1